blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2985293

EP2985293 - IL1RAP EXPRESSION ON ACUTE AND CHRONIC MYELOID LEUKEMIA CELLS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.10.2023
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  28.10.2022
FormerGrant of patent is intended
Status updated on  19.06.2022
FormerExamination is in progress
Status updated on  27.01.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Cantargia AB
Scheelevägen 27
223 63 Lund / SE
[2020/52]
Former [2016/07]For all designated states
Cantargia AB
Medicon Village
Scheelevägen 2
223 81 Lund / SE
Inventor(s)01 / FIORETOS, Thoas
Glasmästarevägen 4
S-227 30 Lund / SE
02 / JÄRÅS, Marcus
Linnegatan 8A
S-224 60 Lund / SE
 [2016/07]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2022/48]Potter Clarkson
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2016/07]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date15187838.620.08.2010
[2016/07]
Priority number, dateUS20090272146P21.08.2009         Original published format: US 272146 P
GB2009001464421.08.2009         Original published format: GB 0914644
US20100296143P19.01.2010         Original published format: US 296143 P
[2016/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2985293
Date:17.02.2016
Language:EN
[2016/07]
Type: B1 Patent specification 
No.:EP2985293
Date:30.11.2022
Language:EN
[2022/48]
Search report(s)(Supplementary) European search report - dispatched on:EP19.01.2016
ClassificationIPC:C07K16/28, C07K16/30, A61K38/00, A61P35/02, G06Q50/30, A61P43/00
[2022/25]
CPC:
C07K16/3061 (EP,CN,GB,US); C07K16/2866 (EP,CN,US); A61K38/177 (GB);
C12Q1/6886 (US); A61K39/39558 (GB); A61K45/00 (GB);
A61P35/02 (EP); A61P43/00 (EP); C07K16/32 (GB);
G01C21/3667 (US); G01N33/57505 (US); G06Q50/40 (EP,US);
G08G1/202 (US); G08G1/205 (US); H04W4/029 (US);
H04W8/24 (US); A61K38/00 (EP,US); C07K2317/73 (US);
C07K2317/732 (CN,US); C07K2317/76 (US); C12Q2600/158 (US);
G01N2333/7155 (US); H04M2250/10 (US) (-)
Former IPC [2016/07]C07K16/28, C07K16/30, A61K38/00, A61P35/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2016/07]
TitleGerman:IL1RAP-EXPRESSION AUF ZELLEN MIT AKUTER UND CHRONISCHER MYELOISCHER LEUKÄMIE[2016/07]
English:IL1RAP EXPRESSION ON ACUTE AND CHRONIC MYELOID LEUKEMIA CELLS[2016/07]
French:IL1RAP EXPRESSION SUR DES CELLULES DE LA LEUCÉMIE MYÉLOÏDE AIGUË ET CHRONIQUE[2016/07]
Examination procedure01.10.2015Examination requested  [2016/07]
16.08.2016Amendment by applicant (claims and/or description)
27.01.2017Invitation to indicate the basis for amendments (Time limit: M01)
03.02.2017Reply to an invitation to indicate the basis for amendments
08.06.2017Despatch of a communication from the examining division (Time limit: M06)
08.12.2017Reply to a communication from the examining division
31.07.2018Despatch of a communication from the examining division (Time limit: M06)
08.02.2019Reply to a communication from the examining division
19.06.2019Despatch of a communication from the examining division (Time limit: M04)
11.10.2019Reply to a communication from the examining division
30.04.2020Despatch of a communication from the examining division (Time limit: M06)
05.11.2020Reply to a communication from the examining division
20.06.2022Communication of intention to grant the patent
19.10.2022Fee for grant paid
19.10.2022Fee for publishing/printing paid
19.10.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10805719.1  / EP2467403
Opposition(s)31.08.2023No opposition filed within time limit [2023/45]
Fees paidRenewal fee
01.10.2015Renewal fee patent year 03
01.10.2015Renewal fee patent year 04
01.10.2015Renewal fee patent year 05
01.10.2015Renewal fee patent year 06
24.08.2016Renewal fee patent year 07
08.08.2017Renewal fee patent year 08
27.08.2018Renewal fee patent year 09
07.08.2019Renewal fee patent year 10
10.08.2020Renewal fee patent year 11
13.08.2021Renewal fee patent year 12
30.08.2022Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY20.08.2010
HU20.08.2010
AL30.11.2022
AT30.11.2022
BG30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
TR30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
IE20.08.2023
LU20.08.2023
[2026/04]
Former [2025/39]CY20.08.2010
HU20.08.2010
AL30.11.2022
AT30.11.2022
BG30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
IE20.08.2023
LU20.08.2023
Former [2025/36]CY20.08.2010
AL30.11.2022
AT30.11.2022
BG30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
IE20.08.2023
LU20.08.2023
Former [2024/51]AL30.11.2022
AT30.11.2022
BG30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
IE20.08.2023
LU20.08.2023
Former [2024/33]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
IE20.08.2023
LU20.08.2023
Former [2024/26]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
IT30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
LU20.08.2023
Former [2024/21]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
LU20.08.2023
Former [2024/16]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
MC30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/51]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SI30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/38]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SK30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/37]AL30.11.2022
AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/35]AT30.11.2022
CZ30.11.2022
DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
RO30.11.2022
SE30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/34]DK30.11.2022
EE30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
SE30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/33]DK30.11.2022
ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
SE30.11.2022
SM30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/29]ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
NL30.11.2022
PL30.11.2022
SE30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/26]ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
PL30.11.2022
SE30.11.2022
NO28.02.2023
GR01.03.2023
IS30.03.2023
PT31.03.2023
Former [2023/24]ES30.11.2022
FI30.11.2022
HR30.11.2022
LT30.11.2022
LV30.11.2022
SE30.11.2022
NO28.02.2023
GR01.03.2023
PT31.03.2023
Former [2023/23]ES30.11.2022
FI30.11.2022
LT30.11.2022
LV30.11.2022
SE30.11.2022
NO28.02.2023
GR01.03.2023
PT31.03.2023
Former [2023/22]ES30.11.2022
FI30.11.2022
LT30.11.2022
SE30.11.2022
NO28.02.2023
PT31.03.2023
Former [2023/20]LT30.11.2022
NO28.02.2023
Documents cited:Search[X] WO9623067  (HOFFMANN LA ROCHE et al.) [X] 1,2,6 * the whole document *
 [X] WO2004100987  (REGENERON PHARMA et al.) [X] 1,2,6 * the whole document *
 [XP] WO2009120903  (CELLERANT THERAPEUTICS INC et al.) [XP] 1-15 * the whole document *
 [X] US2003026806  (WITTE ALISON et al.) [X] 1,2,6 * the whole document *
 [X] WO03014309  (IMMUNEX CORP et al.) [X] 1,2,6 * the whole document *
 [X] WO2006110593  (MACROGENICS INC et al.) [X] 1,2,6 * the whole document *
 [I]   MAJETI RAVINDRA ET AL: "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.", CELL 23 JUL 2009 LNKD- PUBMED:19632179, vol. 138, no. 2, 23 July 2009 (2009-07-23), pages 286 - 299, XP002632714, ISSN: 1097-4172 [I] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/J.CELL.2009.05.045
Examination  PATRICK M. GLASSMANT JOSEPH R BALTHASAR: "Mechanistic considerations for the use of monoclonal antibodies for cancer therapy", CANCER BIOL MED 2014;11:20-33. DOI: 10.7497/J.ISSN.2095-3941.2014.01.002, 1 January 2014 (2014-01-01), China, pages 20 - 33, XP055378099, Retrieved from the Internet [retrieved on 20170601], DOI: 10.7497/j.issn.2095-3941.2014.01.002

DOI:   http://dx.doi.org/10.7497/j.issn.2095-3941.2014.01.002
   CAI ET AL: "Monoclonal antibodies for cancer therapy approved by FDA", 1 January 2016 (2016-01-01), XP055922212, Retrieved from the Internet [retrieved on 20220517]
   HELENA GERSTAM ET AL: "Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 34, 10 August 2015 (2015-08-10), pages 10786 - 10791, XP055308490, ISSN: 0027-8424, DOI: 10.1073/pnas.1422749112

DOI:   http://dx.doi.org/10.1073/pnas.1422749112
   ANNE M LEWIS ET AL: "Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 4, no. 1, 1 January 2006 (2006-01-01), pages 48, XP055494595, ISSN: 1479-5876, DOI: 10.1186/1479-5876-4-48

DOI:   http://dx.doi.org/10.1186/1479-5876-4-48
   HELEN AGERSTAM ET AL: "Regular Article MYELOID NEOPLASIA", 1 January 2016 (2016-01-01), XP055494589, Retrieved from the Internet [retrieved on 20180723], DOI: 10.1182/blood-

DOI:   http://dx.doi.org/10.1182/blood-2015-11-679985
   SERENGULAM V. GOVINDAN ET AL: "New Antibody Conjugates in Cancer Therapy", THE SCIENTIFIC WORLD JOURNAL, vol. 10, 1 January 2010 (2010-01-01), pages 2070 - 2089, XP055319602, DOI: 10.1100/tsw.2010.191

DOI:   http://dx.doi.org/10.1100/tsw.2010.191
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.